No treatment-related deaths occurred from CAR-T toxicity.<h4>Conclusion</h4>These preliminary findings suggest that CD19 and CD22 CAR-T cell therapy may provide long-term survival benefits in pediatric patients with R/R Ph<sup>+</sup> ALL, with manageable toxicity. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.